Pharmacy Daily | J&J sees 2012 dip

JOHNSON & Johnson sales decreased 0.2% year-on-year in the first quarter of 2012 to US$16.1 billion, whilst the company also posted net earnings for the period of US$3.9 billion. First quarter 2012 net earnings included an after-tax gain of US$106 million which has been attributed to the currency adjustment associated with the planned acquisition of Synthes. Meanwhile the company also updated its earnings guidance for full-year 2012 to between US$5.07 and US$5.17 per share, which reflects the positive impact of current exchange rates. "We continue to bring meaningful innovations to our patients and customers through the strong performance of our recently launched products," said J&J CEO and Chairman William Weldon. “The dedication of the people of Johnson & Johnson gives me great confidence in the prospects of our business to deliver sustainable growth, well into the future,” he added.

---

The above article was sent to subscribers in Pharmacy Daily's issue from 18 Apr 12
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 18 Apr 12